Hyperparathyroidism and the calcium paradox of aldosteronism

Circulation

Volumn 111, Issue 7, 2005, Pages 871-878

  Chhokar, Vikram S ^a   Sun, Yao ^a   Bhattacharya, Syamal K ^a   Ahokas, Robert A ^a   Myers, Linda K ^a   Xing, Zhiqing ^a   Smith, Richard A ^a   Gerling, Ivan C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosterone; Calcium; Magnesium; Osteoporosis; Parathyroid hormone

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ALPHA 1 ANTITRYPSIN; CALCIUM ION; HORMONE RECEPTOR BLOCKING AGENT; HYDROGEN PEROXIDE; MAGNESIUM ION; PARATHYROID HORMONE; SODIUM CHLORIDE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE STRENGTH; CALCIUM EXCRETION; CALCIUM PARADOX; CALCIUM URINE LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART VENTRICLE; HORMONE DETERMINATION; HYPERALDOSTERONISM; HYPERPARATHYROIDISM; LYMPHOCYTE; MAGNESIUM EXCRETION; MAGNESIUM URINE LEVEL; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; BONE DENSITY; BONE RESORPTION; CALCIUM; HYPERALDOSTERONISM; HYPERPARATHYROIDISM; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MAGNESIUM; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SPIRONOLACTONE;

EID: 14044258663     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000155621.10213.06     Document Type: Article

References (60)

1. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
2. Miyamoto M, Kishimoto C, Shioji K, Lee JD, Shimizu H, Ueda T, Yodoi J. Cutaneous arteriolar thioredoxin expression in patients with heart failure. Circ J. 2003;67:116-118.
3. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res. 2001;89:279-286.
4. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, Nakamura K, Ichikawa K, Utsumi H, Takeshita A. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation. 2001;104:134-136.
5. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999;83:612-615.
6. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
7. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, Postlethwaite AE, Weber KT. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H813-H821.
8. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L, Bhattacharya SK, Postlethwaite AE, Weber KT. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res. 2003;93:e124-e135.
9. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43:716-719.
10. Hall CE, Hall O. Hypertension and hypersalimentation, I: aldosterone hypertension. Lab Invest. 1965;14:285-294.
11. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67:1355-1364.
12. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
13. Sun Y, Zhang J, Zhang JQ, Ramires FJA. Local angiotensin II and transforming growth factor-β1 in renal fibrosis of rats. Hypertension. 2000;35:1078-1084.
14. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
15. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 1995;27:1545-1560.
16. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
17. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55.
18. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
19. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
20. Delva P, Pastori C, Degan M, Montesi G, Brazzarola P, Lechi A. Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. Hypertension. 2000;35:113-117.
21. Suki WN, Schwettmann RS, Rector FC Jr, Seldin DW. Effect of chronic mineralocorticoid administration on calcium excretion in the rat. Am J Physiol. 1968;215:71-74.
22. Massry SG, Coburn JW, Chapman LW, Kleeman CR. The effect of long-term desoxycorticosterone acetate administration on the renal excretion of calcium and magnesium. J Lab Clin Med. 1968;71:212-219.
23. Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol. 1986;251:F879-F888.
24. Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron. 1988;48:280-283.
25. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. Kidney Int. 1972;2:279-286.
26. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187-1192.
27. Bhattacharya SK, Williams JC. Modified method of urinary calcium and magnesium determinations by atomic absorption spectrophotometry using nitrous oxide-acetylene flame. Anal Lett. 1979;12:397-414.
28. Bhattacharya SK, Williams JC, Palmieri GMA. Determination of calcium and magnesium in cardiac and skeletal muscles by atomic absorption spectroscopy using stoichiometric nitrous oxide-acetylene flame. Anal Lett. 1979;12:1451-1475.
29. Nagy TR, Prince CW, Li J. Validation of peripheral dual-energy X-ray absorptiometry for the measurement of bone mineral in intact and excised long bones of rats. J Bone Miner Res. 2001;16:1682-1687.
30. Combs NR, Kornegay ET, Lindemann MD, Notter DR, Wilson JH, Mason JP. Calcium and phosphorus requirement of swine from weaning to market weight, II: development of response curves for bone criteria and comparison of bending and shear bone testing. J Anim Sci. 1991;69:682-693.
31. Sheppard K, Funder JW. Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. Am J Physiol. 1987;252:E224-E229.
32. Zikos D, Langman C, Gafter U, Delahaye B, Lau K. Chronic DOCA treatment increases Ca absorption: role of hypercalciuria and vitamin D. Am J Physiol. 1986;251:E279-E284.
33. Berthelot A, Pernot F, Gairard A. Influence of the thyroid and parathyroid glands on magnesium metabolism during mineralocorticoid treatment (DOCA + NaCl) in the rat. Ann Nutr Metab. 1983;27:349-354.
34. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-893.
35. Sellmeyer DE, Schloetter M, Sebastian A. Potassium citrate prevents increased urine calcium excretion and bone resorption induced by a high sodium chloride diet. J Clin Endocrinol Metab. 2002;87:2008-2012.
36. Chan EL, Swaminathan R. Effect of different amounts of sodium intake for 4 months on calcium metabolism in normal and oophorectomized rats. J Bone Miner Res. 1993;8:1185-1189.
37. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation. 1998;98:2621-2628.
38. Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens. 2003;16:319-323.
39. Zou AP, Cowley AW Jr. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1:178-186.
40. Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197-R202.
41. Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad Med J. 1980;56:45-47.
42. Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 1980;244:1351-1353.
43. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385-390.
44. Palmieri GM, Hawrylko J. Effects of aldosterone on the urinary excretion of total and non-dialyzable hydroxyproline. Horm Metab Res. 1977;9: 507-509.
45. Goulding A, Campbell D. Dietary NaCl loads promote calciuria and bone loss in adult oophorectomized rats consuming a low calcium diet. J Nutr. 1983;113:1409-1414.
46. Creedon A, Cashman KD. The effect of high salt and high protein intake on calcium metabolism, bone composition and bone resorption in the rat. Br J Nutr. 2000;84:49-56.
47. Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Rudikoff S, Jilka RL, Manolagas SC, Insogna K. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology. 1999;140:4683-4690.
48. Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure. Z Kardiol. 1992;81:121-125.
49. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Shimoyama M, Kinugawa T, Osaki S, Kato M, Tomikura Y, Igawa O, Hisatome I, Bilezikian JP, Shigemasa C. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722-4727.
50. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-112.
51. Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab. 2000;18:109-125.
52. 2+ current in adult rat cardiomyocytes. Circ Res. 1999;85:1139-1145.
53. Fukuda K, Baba A, Kuchii M, Nakamura Y, Nishio I, Masuyama Y. Increased concentration of calcium channel and intracellular free calcium in the acute phase of deoxycorticosterone acetate salt hypertension. J Hypertens Suppl. 1988;6:S261-S263.
54. Fluckiger JP, Nguyen PV, Li G, Yang XP, Schiffrin EL. Calcium, phosphoinositide, and 1,2-diacylglycerol responses of blood vessels of deoxycorticosterone acetate-salt hypertensive rats to endothelin-1. Hypertension. 1992;19:743-748.
55. Fareh J, Touyz RM, Schiffrin EL, Thibault G. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats. Hypertension. 1997;30:1253-1259.
56. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264;H1998-H2006.
57. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res. 1998;37:34-41.
58. Perry HM 3rd, Chappel JC, Bellorin-Font E, Tamao J, Martin KJ, Teitelbaum SL. Parathyroid hormone receptors in circulating human mononuclear leukocytes. J Biol Chem. 1984;259:5531-5535.
59. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes W. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
60. i and proliferation of B cells from dialysis patients. Kidney Int. 1996;50:1249-1254.